Podcast: Novartis, ML&P and ex-GSK counsel on COVID pools

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Podcast: Novartis, ML&P and ex-GSK counsel on COVID pools

re-podcast-logo.png

Guests debate how patent pools could be used to ensure global access to COVID treatments and vaccines, as well as how the pandemic has changed the IP system


To listen to the podcast, which is nearly 50 minutes, click the link below.

For the first Managing IP podcast, Charlotte Kilpatrick and IP experts discussed the ramifications of the COVID-19 crisis on the patent system and how the virus could change how pharma innovators conduct research and collaborate.

A highlight was a debate on the role patent pools could play to accelerate research for COVID treatments and vaccines. Ellen 't Hoen, director of the Medicines Law and Policy research institute in the Netherlands, stressed the importance for pharma innovators to use patent pools as a way to ensure global access to the vaccines once they become available. She pointed to the example of the Medicines Patent Pool, which negotiates licences for HIV and tuberculosis medications with generics companies, which can produce treatments at an affordable cost for developing countries.

David Rosenberg, former vice president of IP policy at GSK, agreed that a patent pool could be one solution among many to ensure access, but added he doesn’t believe a pool will be the ideal way for companies to conduct business and that innovators are more confident to negotiate with generics companies they already know. 

Corey Salsberg, vice president and global head of IP affairs at Novartis in Washington DC, noted that because tackling COVID-19 could involve multiple vaccines as well as treatments for those with advanced symptoms, a single patent pool might not be the best solution to ensure access.

Enjoy the podcast. 








more from across site and ros bottom lb

More from across our site

Firms explain how they question jurors and account for potential bias in trade secrets cases
A meeting between the EPO and Ericsson, Paul McCartney weighing in on AI and copyright, and a law firm’s STEM pledge were among the top talking points
National courts could combat inconsistencies over the speed of judgments – and provide parties with much-needed certainty – by looking to the UPC
Sources in four jurisdictions discuss the downsides of delayed judgments and why they prefer a well-reasoned, late finding, over a quick ruling that lacks substance
Counsel discuss how likely SCOTUS is to remand closely watched trademark case, which centres on the principle of corporate separateness
Partners at Baker Botts explain why oral arguments were a crucial factor in convincing the Federal Circuit to affirm a lower court ruling
The operator hopes to capitalise on significant market opportunities presented by evolving voice technologies
Stelling is a co-founder of Brand Action
Dixon is president of CIPA, Saliger is president of CITMA, and Tunney is president of APTMA
Gift this article